Skip Navigation U.S. Department of Health and Human Services www.hhs.gov
Agency for Healthcare Research Quality www.ahrq.gov
Archive print banner
Report on the Relative Efficacy of Oral Cancer Therapy for Medicare Beneficiaries Versus Currently Covered Therapy

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to www.ahrq.gov for current information.

Part 3. Imatinib for Chronic Myeloid Leukemia (CML) (continued)


Excluded Articles

1. Abruzzese E, Bocchia M, Trawinska M, et al. Peptide-vaccine treatment associated with imatinib in patients with residual CML disease is able to induce both immunologic response and molecular remission. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14S (July 15 Supplement), 2004: 2517. 2004.

2. Abruzzese E, Gozzetti A, Zaccaria A, et al. Ph-abnormal clones emerged during imatinib therapy: clinical report and clonal analyses on 23 patients from GIMEMA working party (GWP) in CML registry. Blood 2004;104(11):Abstract #2936.

3. Alvarez RH, Kantarjian H, Bueso-Ramos C, et al. Significance of marrow fibrosis in chronic phase chronic myelogenous leukemia (CML) post interferon-a failure treated with imatinib mesylate therapy. Blood 2004;104(11):Abstract #2939.

4. Angstreich GR, Smith BD, Jones RJ. Treatment options for chronic myeloid leukemia: imatinib versus interferon versus allogeneic transplant [Review]. Current Opinion in Oncology 2004;16(2):95-9.

5. Ausekar BV. Comparative study of survival off CML patients under treatment with busulphan, hydroxyurea, interferon A, imatinib. Journal of Clinical Oncology 2004;22(14S):Abstract #6783.

6. Azam M, Latek RR, Daley GQ. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 2003;112(6):831-43.

7. Barbouti A, Ahlgren T, Johansson B, et al. Clinical and genetic studies of ETV6/ABL1-positive chronic myeloid leukaemia in blast crisis treated with imatinib mesylate. British Journal of Haematology 2003;122(1):85-93.

8. Berger U, Engelich G, Reiter A, et al. Imatinib and beyond--the new CML study IV. A randomized controlled comparison of imatinib vs imatinib/interferon-alpha vs imatinib/low-dose AraC vs imatinib after interferon-alpha failure in newly diagnosed chronic phase chronic myeloid leukemia. Annals of Hematology 2004;83(4):258-64.

9. Blasiak J, Drzewoski J, Poplawski T, et al. Imatinib (STI571) induces DNA damage in BCR/ABL-expressing leukemic cells but not in normal lymphocytes. Blood 2004;104(11):Abstract #4353.

10. Borthakur G, Cortes J. Imatinib mesylate in the treatment of chronic myelogenous leukemia [Review]. International Journal of Hematology 2004;79(5):411-9.

11. Brieger A, Boehrer S, Schaaf S, et al. In bcr-abl-positive myeloid cells resistant to conventional chemotherapeutic agents, expression of Par-4 increases sensitivity to imatinib (STI571) and histone deacetylase-inhibitors. Biochemical Pharmacology 2004;68(1):85-93.

12. Bueso-Ramos CE, Cortes J, Talpaz M, et al. Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia. Cancer 2004;101(2):332-6.

13. Canadian Coordinating Office for Health Technology Assessment. 2001 [Accessed at https://www.ccohta.ca/entry_e.html, September 23, 2005]

14. Cazzaniga G, Corradi B, Piazza R, et al. Highly sensitive mutations detection in BCR-ABL positive leukemia prior and during imatinib treatment. Blood 2004;104(11):Abstract #1985.

15. Champlin R, Ghosh S, McCormick G, et al. Sequential treatment with reduced intensity allogeneic stem cell transplantation and imatinib for chronic myelogenous leukemia (CML). Blood 2004;104(11):Abstract #812.

16. Chandra J, Tracy, Gorre M, et al. Effects of adaphostin, a novel tyrphostin inhibitor, in diverse models of imatinib mesylate resistance. Blood 2004;104(11):Abstract #2097.

17. Corbin AS, Buchdunger E, Pascal F, et al. Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571. Journal of Biological Chemistry 2002;277(35):32214-9.

18. Cortes J. Randomized trial of therapy of early phase chronic myelogenous leukemia with high-dose imatinib mesylate (Gleevec) alone or in combination with peg-alpha interferon (PEG-Intron) and sargramostin (GM-CSF). National Institutes of Health, Clinicial Trials. 2003 [Accessed at http://www.clinicaltrials.gov/ct/show/NCT00050531?order=45=, September 23, 2005]

19. Deininger MW, Druker BJ. Specific targeted therapy of chronic myelogenous leukemia with imatinib [Review]. Pharmacological Reviews 2003;55(3):401-23.

20. Deininger MW, O'Brien S, Ford JM, et al. Practical management of patients with chronic myeloid leukemia receiving imatinib [Review]. Journal of Clinical Oncology 2003;21(8):1637-47.

21. Deininger MW, Schleuning M, Sayer H-G, et al. Allografting after imatinib therapy. No evidence for increased transplant-related mortality and favorable results in patients transplanted in remission. A retrospective study by the EBMT. Blood;100:783a.

22. Demehri S, Lange T, Paschka P, et al. CML with E8A2 BCR-ABL fusion: the fourth breakpoint cluster region? Blood 2004;104(11):Abstract #1018.

23. Druker BJ. Signal transduction inhibition: results from phase I clinical trials in chronic myeloid leukemia [Review]. Seminars in Hematology 2001;38(3 Suppl 8):9-14.

24. Druker BJ. Taking aim at Ewing's sarcoma: is KIT a target and will imatinib work? Journal of the National Cancer Institute 2002, 94: 1660-1

25. Druker BJ. Imatinib mesylate in the treatment of chronic myeloid leukaemia. [Review]. Expert Opinion on Pharmacotherapy 2003;4(6):963-71.

26. Ebnoether M, Stentoft J, Ford JM, et al. Cerebral oedema as a possible complication of treatment with imatinib. Lancet 2002;359(9319):1751-2.

27. Elliot VJ, Marin D, Horncastle D, et al. Percentage of CD34 + cells in a minimum 500-cell count in bone marrow trephines of patients with chronic myeloid leukaemia provides the best correlation with aspirate blast count. Blood 2004;104(11):Abstract #4663.

28. Engelich G, Berger U, Hochhaus A, et al. Randomized controlled comparison of imatinib vs. imatinib + interferon alpha vs. imatinib + low dose araC vs. interferon a standard therapy and determining the role of allografting vs. salvage chemotherapy in newly diagnosed chronic phase CML. Onkologie 2002;25(Suppl 4):174.

29. Faber E, Jarosova M, Nausova J, et al. Intermittent dosage of imatinib—a feasible strategy for patients with significant hematologic toxicity during standard therapy. Blood 2004;104(11):Abstract #4657.

30. Gambacorti-Passerini C, Tornaghi L, Cavagnini F, et al. Gynaecomastia in men with chronic myeloid leukaemia after imatinib_ . Lancet 2003;361:1954–56.

31. Garside R, Round A, Dalziel K, et al. The effectiveness and cost-effectiveness of imatinib in chronic myeloid leukaemia: a systematic review [Review]. Health Technology Assessment 2002;6(33):1-162.

32. Goldman JM. Chronic myeloid leukemia—still a few questions. Experimental Hematology 2004;32:2-10.

33. Gordois A, Scuffham P, Warren E, et al. Cost-utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukaemia. British Journal of Cancer 2003;89(4):634-40.

34. Gratwohl A, Hermans J, Goldman JM, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic Blood or marrow transplantation. Lancet 1998;352:1087–92.

35. Griswold IJ, Bumm T, O'Hare T, et al. Investigation of the biological differences between BCR-ABL kinase mutations resistant to imatinib. Blood 2004;104(11):Abstract #555.

36. Guilhot F. Imatinib (Gleevec, Glivec) versus interferon (IFN) + cytarabine as initial therapy for patients with chronic myeloid leukaemia (CML) in chronic phase: results of a randomized study (for the IRIS group). Annals of Oncology 2002;13(Suppl 5):8, Abs. 27.

37. Guilhot F, O'Brien S, Druker BJ, et al. Imatinib (ST1571, Glivec(r)) as initial therapy for patients with CML: results of a randomized phase III study versus interferon (IFN) cytarabine [abstract]. Hematology Journal 2002;3(Suppl 1):181.

38. Gulbas Z, Akay MO, Sahin F, et al. Chronic myeloid leukemia patients treated with imatinib show increased IFN-gamma synthesis in T Cells and hypogammaglobulinemia. Blood 2004;104(11):Abstract #4698.

39. Gupta S, Berman E, Jhanwar S. Results of conventional cytogenetics and interphase FISH (I-FISH) analyses in patients with a clinical and morphologic diagnosis of CML: analysis of 52 cases. Blood 2004;104(11):Abstract #4423.

40. Hahn EA. The quality of life of patients with chronic phase chronic myeloid leukemia in the IRIS study of interferon-alpha plus ARA-C vs imatinib (ST1571, Glivec(r)) [abstract]. Hematology Journal 2002;3(Suppl 1):300.

41. Hahn EA, Sorensen MV, Hudgens SA, et al. Quality of life of patients with chronic phase chronic myeloid leukemia in the IRIS study of interferon-alpha plus Ara-C vs imatinib (ST1571, Glivec, Gleevec0 [abstract]. Blood 2002;100(11):94a.

42. Hehlmann R. Phase III randomized pilot study of imatinib mesylate alone or with interferon alfa or low-dose cytarabine versus interferon alfa standard therapy followed by allogeneic stem cell transplantation in patients with newly diagnosed chronic phase chronic myelogenous leukemia. National Institutes of Health, Clinical Trials 2003 [Accessed at http://www.clinicaltrials.gov, September 23, 2005].

43. Homewood J, Watson M, Richards SM, et al. Treatment of CML using IFN-alpha: impact on quality of life. Hematology Journal 2003;4(4):253-62.

44. Hughes T, Branford S. Molecular monitoring of chronic myeloid leukemia. [Review]. Seminars in Hematology 2003;40(2 Suppl 2):62-8.

45. Husereau D. Imatinib mesylate for chronic myeloid leukemia: what do we really know? Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA) 2002.

46. Ichihara E, Costa FF, Busoli N, et al. High frequency of point mutations of BCR/ABL gene in CML patients resistant to imatinib therapy—report of a novel mutation. Blood 2004;104(11):Abstract #4661.

47. Illmer T, Schaich M, Platzbecker U, et al. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 2004;18(3):401-8.

48. Jiang X, Zhao Y, Chan WY, et al. Leukemic stem cells of chronic phase CML patients consistently display very high BCR-ABL transcript levels and reduced responsiveness to imatinib mesylate in addition to generating a rare subset that produce imatinib mesylate-resistant differentiated progeny. Blood 2004;104(11):Abstract #711.

49. Jilani I, Vincente T, Faraji H, et al. Circulating myeloperoxidase (MPO) as a tumor marker in patients with chronic myeloid leukemia (CML). Blood 2004;104(11):Abstract #4679.

50. Kai T, Ikeda K, Shiga Y, et al. Imatinib mesylate induced fatal hepatitis B virus (HBV) reactivation in a patient with CML. Blood 2004;104(11):Abstract #4677.

51. Kantarjian H, Cortes J, O'Brien S, et al. Long-term results of imatinib mesylate therapy in philadelphia chromosome (Ph) positive chronic phase chronic myelogenous leukemia (CML) post interferon-a (IFN) failure. M.D. Anderson experience in 261 patients. Journal of Clinical Oncology 2004;22(1: 4S (July 15 Supplement),):Abstract 6622.

52. Kantarjian H, O'Brien S, Cortes J, et al. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase. Cancer 2003;98(7):1430-7.

53. Kim J, Kim D, Lee D, et al. Monitoring of BCR-ABL Transcirpt Levels after Discontinuation of Imatinib Therapy in Chronic Myelogenous Leukemia Patients Achieving Complete Cytogenetic Response. Blood 2004;104(11):Abstract #4684.

54. Koyama N, Koschmieder S, Tyagi S, et al. Inhibition of phosphotyrosine phosphatase-1B (PTP1B) induces resistance to the ABL kinase inhibitor imatinib mesylate (Gleevec®) in BCR-ABL positive leukemic cells. Blood 2004;104(11):Abstract #2095.

55. Kurzrock R, Talpaz M, Li L, et al. Distinct biological impact of dephosphorylation vs downregulation of p210 Bcr-Abl: implications for imatinib mesylate response and resistance. Blood 2004;104(11):Abstract #4307.

56. Kwak J, Lee N, Song E, et al. The change of vascular endothelial growth factor and microvessel density following imatinib mesylate therapy and allogeneic bone marrow transplantation in chronic myeolid leukemia. Blood 2004;104(11):Abstract #4669.

57. Larson RA, IRIS Study Group. Imatinib (ST1571, Gleevec) as initial therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia (CML): results of a randomized Phase III study vs interferon-alfa + cytarabine (IFN+AraC) [abstract]. Blood 2002;100:4a.

58. Latagliata R, Breccia M, Carmosino I, et al. Association of hydroxyurea to imatinib is effective in patients with chronic myelogenous leukemia resistant to imatinib alone. Blood 2004;104(11):Abstract #4693.

59. Leis JF, Stepan DE, Curtin PT, et al. Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571). Leukemia & Lymphoma 2004;45(4):695-8.

60. Lickliter J, Arthur C, D'Rozario J, et al. Phase II pilot study of imatinib mesylate combined with induction chemotherapy in blast-phase CML and Ph+ ALL. Blood 2004;104(11):Abstract #4682.

61. Lin F, Drummond MW, O'Brien S, et al. Molecular monitoring in chronic myeloid leukemia patients who achieve complete cytogenetic remission on imatinib. Blood 2003;102(3):1143.

62. Martinelli G, Rosti G, Pane F, et al. Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients by GIMEMA Working Party on CML. Blood 2004;104(11):Abstract #4672.

63. Matsui W, Angstreich GR, Vala MS, et al. Chronic myeloid leukemia stem cells and their differentiated progeny display divergent drug sensitivities to imatinib mesylate and interferon-alpha. Blood 2004;104(11):Abstract #1996.

64. McNamara C, Grigg A, Szer J, et al. Morphological effects of imatinib mesylate (STI571) on the bone marrow and Blood of patients with Philadelphia chromosome (Ph) positive chronic myeloid leukaemia. Clinical & Laboratory Haematology 2003;25(2):119-25.

65. McPherson E, Shanmughan M, Huang SY, et al. Response of elevated serum soluble interleukin-2 receptor (sIL-2R) and overexpression of glucose-6-phosphate dehydrogenase (G6PD) in patients with chronic myelogenous leukemia treated with imatinib mesylate. Blood 2004;104(11):Abstract #4695.

66. Miljus j, Melo JV, Boros L, et al. Metabolic profile of imatinib resistance in CML cells. Blood 2004;104(11):Abstract #1982.

67. Miyoshi T, Nagai T, Nakamura M, et al. Heme affects sensitivity to imatinib through regulation of Nrf2 Activity in BCR/ABL-positive cell lines. Blood 2004;104(11):Abstract #2092 .

68. National Institute for Clinical Excellence. Guidance on the use of imatinib for chronic myeloid leukaemia. London: National Institute for Clinical Excellence (NICE) 2002.

69. Neumann F, Teutsch N, Kliszewski S, et al. Gene expression profiling of Philadelphia chromosome (Ph) Negative CD34+ hematopoietic stem and progenitor cells of patients with Ph positive CML in complete molecular remission during therapy with imatinib. Leukemia 2005;104(19):458-60.

70. Novaretti MC, Fonseca GH, Conchon M, et al. First case of immune-mediated haemolytic anaemia associated to imatinib mesylate. European Journal of Haematology 2003;71(6):455-8.

71. O'Brien S, Deininger MW. Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia. Seminars in Hematology 2003;40(2 Suppl 2):26-30.

72. O'Brien S, Rule SA. Position paper on imatinib mesylate in chronic myeloid leukaemia. British Journal of Haematology 2002;119(1):268-72.

73. Ottmann OG, Druker BJ, Sawyers CL, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002;100(6):1965-71.

74. Ptasznik A, Nakata Y, Kalota A, et al. Targeting lyn kinase with short interfering RNA (siRNA)—a novel therapeutic strategy for drug resistant chronic myelogenous leukemia (CML). Blood 2004;104(11):Abstract #554.

75. Radujkovic A, Schad M, Topaly J, et al. Synergism between 17-AAG and imatinib in imatinib-resistant CML Cells: inhibition of p-glycoprotein by 17-AAG as a new mechanism of increasing imatinib activity. Blood 2004;104(11):Abstract #2094.

76. Reinhold U, Hennig E, Leiblein S, et al. FISH for BCR-ABL on interphases of peripheral Blood neutrophils but not of unselected white cells correlates with bone marrow cytogenetics in CML patients treated with imatinib. Leukemia 2003;17(10):1925-9.

77. Rosti G, Trabacchi E, Bassi S, et al. Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia. Haematologica 2003;88(3):256-9.

78. Sashida G, Tauchi T, Sumi M, et al. Specific inhibition of hTERT by shRNA sensitizes for imatinib mesylate in BCR-ABL-positive cells. Blood 2004;104(11):Abstract #4339.

79. Sawyers CL. Research on resistance to cancer drug Gleevec. Science 2001;294:1834.

80. Schoch CSS, Bursch S, Gerstner D, et al. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia 2002;16:53–59.

81. Segawa H, Kimura S, Kuroda J, et al. Zoledronate inhibits leukemia growth in bone marrow and synergizes with imatinib mesylate against Ph+ primary leukemic cells. Blood 2004;104(11):Abstract #2096.

82. Shah NP, Branford S, Hughes TP, et al. Major cytogenetic responses to BMS-354825 in patients with chronic myeloid leukemia are associated with a one to two log reduction in BCR-ABL transcript. Blood 2004;104(11):Abstract #1008.

83. Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305:399-401.

84. Shimizu T, Miyakawa Y, Iwata S, et al. A novel mechanism for imatinib mesylate (STI571) resistance in CML cells: contribution of TC-PTP to modulating signals down-stream from the BCR-ABL fusion protein. Blood 2004;104(11):Abstract #1984.

85. Siciliano RD, Schmid M, Stussi G, et al. Continuous complete molecular remission after withdrawal of imatinib mesylate in relapsed CML after allogeneic stem cell transplantation. Blood 2004;104(11):Abstract #4686.

86. Silver RT. Molecular Biology of CML. In RC Bast, D Kufe, RE Pollock, et al. Cancer Medicine (Ed. 5) Hamilton, Ontario: BC Decker 2000.

87. Silver RT, Peterson BL, Szatrowski TP, et al. Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013. Leukemia & Lymphoma 2003;44(1):39-48.

88. Sotiropoulos D, Adamidou D, Athanasiadou A, et al. two pregnancies resulting in a healthy newborn in a CML patient treated with imatinib. Blood 2004;104(11):Abstract #4694.

89. Soverini S, Martinelli G, Rosti G, et al. ABL mutations in late-chronic phase chronic myeloid leukemia patients with cytogenetic refractoriness to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival. On Behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia. Blood 2004;104(11):Abstract #1005.

90. Tipping AJ, Deininger MW, Goldman JM, et al. Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate. Experimental Hematology 2003;31(11):1073-80.

91. Tsao AS, Kantarjian H, Cortes J, et al. Imatinib mesylate causes hypopigmentation in the skin. Cancer 2003;98(11):2483-7.

92. van Deventer HW, Hall MD, Orlowski RZ, et al. Clinical course of thrombocytopenia in patients treated with imatinib mesylate for accelerated phase chronic myelogenous leukemia. American Journal of Hematology 2002;71(3):184-90.

93. Vandenberghe P, Boeckx N, Ronsyn E, et al. Imatinib mesylate induces durable complete remission of advanced CML persisting after allogeneic bone marrow transplantation. Leukemia 2003;17(2):458-60.

94. Vidal, Kantarjian H, O'Brien S, et al. Sudden blastic transformation (SBT) in patients (pts) with chronic myeloid leukemia (CML) treated with imatinib mesylate. Blood 2004;104(11):Abstract #2930.

95. Wassmann B, Gokbuget N, Bruck P, et al. 2003.

96. Wassmann B, Gokbuget N, Scheuring UJ, et al. A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chromosome-positive (Ph+/BCR-ABL+) acute lymphoblastic leukemia (ALL) (CSTI571ADE 10). Annals of Hematology 2003;82(11):716-20.

97. Zander AR, Zabelina T, Renges H, et al. Pretreatment with Glivec Increases Transplant-Related Mortality after Allogeneic Transplant. Blood 2003;102(21):468a.

Return to Contents
Proceed to Next Section

The information on this page is archived and provided for reference purposes only.

 

AHRQ Advancing Excellence in Health Care